Literature DB >> 7942841

Osteogenesis imperfecta type I: molecular heterogeneity for COL1A1 null alleles of type I collagen.

M C Willing1, S P Deschenes, D A Scott, P H Byers, R L Slayton, S H Pitts, H Arikat, E J Roberts.   

Abstract

Osteogenesis imperfecta (OI) type I is the mildest form of inherited brittle-bone disease. Dermal fibroblasts from most affected individuals produce about half the usual amount of type I procollagen, as a result of a COL1A1 "null" allele. Using PCR amplification of genomic DNA from affected individuals, followed by denaturing gradient gel electrophoresis (DGGE) and SSCP, we identified seven different COL1A1 gene mutations in eight unrelated families with OI type I. Three families have single nucleotide substitutions that alter 5' donor splice sites; two of these unrelated families have the same mutation. One family has a point mutation, in an exon, that creates a premature termination codon, and four have small deletions or insertions, within exons, that create translational frameshifts and new termination codons downstream of the mutation sites. Each mutation leads to both marked reduction in steady-state levels of mRNA from the mutant allele and a quantitative decrease in type I procollagen production. Our data demonstrate that different molecular mechanisms that have the same effect on type I collagen production result in the same clinical phenotype.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7942841      PMCID: PMC1918287     

Source DB:  PubMed          Journal:  Am J Hum Genet        ISSN: 0002-9297            Impact factor:   11.025


  50 in total

1.  Osteogenesis imperfecta due to recurrent point mutations at CpG dinucleotides in the COL1A1 gene of type I collagen.

Authors:  C J Pruchno; D H Cohn; G A Wallis; M C Willing; B J Starman; X M Zhang; P H Byers
Journal:  Hum Genet       Date:  1991-05       Impact factor: 4.132

2.  A sequence polymorphism in the 3'-nontranslated region of the pro alpha 1 chain of type I procollagen.

Authors:  A I Westerhausen; C D Constantinou; D J Prockop
Journal:  Nucleic Acids Res       Date:  1990-08-25       Impact factor: 16.971

3.  PvuII polymorphism at the COL1A2 locus.

Authors:  C D Constantinou; L D Spotila; J Zhuang; L Sereda; C Hanning; D J Prockop
Journal:  Nucleic Acids Res       Date:  1990-09-25       Impact factor: 16.971

4.  Complete nucleotide sequence of the region encompassing the first twenty-five exons of the human pro alpha 1(I) collagen gene (COL1A1)

Authors:  M D'Alessio; M Bernard; P J Pretorius; W de Wet; F Ramirez; P J Pretorious
Journal:  Gene       Date:  1988-07-15       Impact factor: 3.688

5.  Identical G+1 to A mutations in three different introns of the type III procollagen gene (COL3A1) produce different patterns of RNA splicing in three variants of Ehlers-Danlos syndrome. IV. An explanation for exon skipping some mutations and not others.

Authors:  H Kuivaniemi; S Kontusaari; G Tromp; M J Zhao; C Sabol; D J Prockop
Journal:  J Biol Chem       Date:  1990-07-15       Impact factor: 5.157

6.  Transgenic mouse model of the mild dominant form of osteogenesis imperfecta.

Authors:  J Bonadio; T L Saunders; E Tsai; S A Goldstein; J Morris-Wiman; L Brinkley; D F Dolan; R A Altschuler; J E Hawkins; J F Bateman
Journal:  Proc Natl Acad Sci U S A       Date:  1990-09       Impact factor: 11.205

7.  Uroporphyrinogen decarboxylase: a splice site mutation causes the deletion of exon 6 in multiple families with porphyria cutanea tarda.

Authors:  J R Garey; L M Harrison; K F Franklin; K M Metcalf; E S Radisky; J P Kushner
Journal:  J Clin Invest       Date:  1990-11       Impact factor: 14.808

8.  Molecular basis of hereditary C3 deficiency.

Authors:  M Botto; K Y Fong; A K So; A Rudge; M J Walport
Journal:  J Clin Invest       Date:  1990-10       Impact factor: 14.808

9.  Characterization of a splicing mutation in group A xeroderma pigmentosum.

Authors:  I Satokata; K Tanaka; N Miura; I Miyamoto; Y Satoh; S Kondo; Y Okada
Journal:  Proc Natl Acad Sci U S A       Date:  1990-12       Impact factor: 11.205

10.  Distinct biochemical phenotypes predict clinical severity in nonlethal variants of osteogenesis imperfecta.

Authors:  R J Wenstrup; M C Willing; B J Starman; P H Byers
Journal:  Am J Hum Genet       Date:  1990-05       Impact factor: 11.025

View more
  42 in total

1.  Toward an understanding of the cause of mitral valve prolapse.

Authors:  J A Towbin
Journal:  Am J Hum Genet       Date:  1999-11       Impact factor: 11.025

2.  Redefinition of exon 7 in the COL1A1 gene of type I collagen by an intron 8 splice-donor-site mutation in a form of osteogenesis imperfecta: influence of intron splice order on outcome of splice-site mutation.

Authors:  U Schwarze; B J Starman; P H Byers
Journal:  Am J Hum Genet       Date:  1999-08       Impact factor: 11.025

3.  Biochemical screening of type I collagen in osteogenesis imperfecta: detection of glycine substitutions in the amino end of the alpha chains requires supplementation by molecular analysis.

Authors:  W A Cabral; S Milgrom; A D Letocha; E Moriarty; J C Marini
Journal:  J Med Genet       Date:  2006-08       Impact factor: 6.318

Review 4.  Genetic diseases of connective tissues: cellular and extracellular effects of ECM mutations.

Authors:  John F Bateman; Raymond P Boot-Handford; Shireen R Lamandé
Journal:  Nat Rev Genet       Date:  2009-03       Impact factor: 53.242

5.  Mutations in the COL5A1 gene are causal in the Ehlers-Danlos syndromes I and II.

Authors:  A De Paepe; L Nuytinck; I Hausser; I Anton-Lamprecht; J M Naeyaert
Journal:  Am J Hum Genet       Date:  1997-03       Impact factor: 11.025

6.  Risedronate in adults with osteogenesis imperfecta type I: increased bone mineral density and decreased bone turnover, but high fracture rate persists.

Authors:  L A Bradbury; S Barlow; F Geoghegan; R A Hannon; S L Stuckey; J A H Wass; R G G Russell; M A Brown; E L Duncan
Journal:  Osteoporos Int       Date:  2011-07-08       Impact factor: 4.507

Review 7.  New perspectives on osteogenesis imperfecta.

Authors:  Antonella Forlino; Wayne A Cabral; Aileen M Barnes; Joan C Marini
Journal:  Nat Rev Endocrinol       Date:  2011-06-14       Impact factor: 43.330

Review 8.  Consortium for osteogenesis imperfecta mutations in the helical domain of type I collagen: regions rich in lethal mutations align with collagen binding sites for integrins and proteoglycans.

Authors:  Joan C Marini; Antonella Forlino; Wayne A Cabral; Aileen M Barnes; James D San Antonio; Sarah Milgrom; James C Hyland; Jarmo Körkkö; Darwin J Prockop; Anne De Paepe; Paul Coucke; Sofie Symoens; Francis H Glorieux; Peter J Roughley; Alan M Lund; Kaija Kuurila-Svahn; Heini Hartikka; Daniel H Cohn; Deborah Krakow; Monica Mottes; Ulrike Schwarze; Diana Chen; Kathleen Yang; Christine Kuslich; James Troendle; Raymond Dalgleish; Peter H Byers
Journal:  Hum Mutat       Date:  2007-03       Impact factor: 4.878

9.  Two novel COL1A1 mutations in patients with osteogenesis imperfecta (OI) affect the stability of the collagen type I triple-helix.

Authors:  Joanna Witecka; Aleksandra M Auguściak-Duma; Anna Kruczek; Anna Szydło; Marta Lesiak; Maria Krzak; Jacek J Pietrzyk; Minna Männikkö; Aleksander L Sieroń
Journal:  J Appl Genet       Date:  2008       Impact factor: 3.240

10.  Mutation and polymorphism spectrum in osteogenesis imperfecta type II: implications for genotype-phenotype relationships.

Authors:  Dale L Bodian; Ting-Fung Chan; Annie Poon; Ulrike Schwarze; Kathleen Yang; Peter H Byers; Pui-Yan Kwok; Teri E Klein
Journal:  Hum Mol Genet       Date:  2008-11-07       Impact factor: 6.150

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.